Cited by 723Amyotrophic Lateral Sclerosis ResearchHereditary Neurological DisordersAlzheimer's disease research and treatments

TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis

Open access
Van Deerlin, Vivianna M, Leverenz, James B, Bekris, Lynn M, Bird, Thomas D, Yuan, Wuxing, Elman, Lauren B, Clay, Dana, Wood, Elisabeth McCarty +15 more·2008·The Lancet Neurology

Abstract

Background TDP-43 is a major component of the ubiquitinated inclusions that characterise amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) with ubiquitin inclusions (FTLD-U). TDP-43 is an RNA-binding and DNA-binding protein that has many functions and is encoded by the TAR DNA-binding protein gene (TARDBP) on chromosome 1. Our aim was to investigate whether TARDBP is a candidate disease gene for familial ALS that is not associated with mutations in superoxide dismutase 1 (SOD1).Methods TARDBP was sequenced in 259 patients with ALS, FTLD, or both. We used TaqMan-based SNP genotyping to screen for the identified variants in control groups matched to two kindreds of patients for age and ethnic origin. Additional clinical, genetic, and pathological assessments were made in these two families.Findings We identified two variants in TARDBP, which would encode Gly290Ala and Gly298Ser forms of TDP-43, in two kindreds with familial ALS. The variants seem to be pathogenic because they co-segregated with disease in both families, were absent in controls, and were associated with TDP-43 neuropathology in both members of one of these families for whom CNS tissue was available.Interpretation The Gly290Ala and Gly298Ser mutations are located in the glycine-rich domain of TDP-43, which regulates gene expression and mediates protein-protein interactions such as those with heterogeneous ribonucleoproteins. Owing to the varied and important cellular functions of TDP-43, these mutations might cause neurodegeneration through both gains and losses of function. The finding of pathogenic mutations in TARDBP implicates TDP-43 as an active mediator of neurodegeneration in TDP-43 proteinopathies, a class of disorder that includes ALS and FTLD-U.Funding National Institutes of Health (AG10124, AG17586, AG005136-22, PO1 AG14382), Department of Veterans Affairs, Friedrich-Baur Stiftung (0017/2007), US Public Health Service, ALS Association, and Fundació 'la Caixa'.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(08)70071-1

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mutations in TARDBP are the third most common cause of familial autosomal dominant ALS and account for rare cases of sporadic ALS.

    “Mutations in TARDBP, which encodes the transactive response DNA binding protein 43 kDa (TDP-43), are the third most common cause of familial autosomal dominant ALS and account for rare cases of sporadic ALS [290–293].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Van Deerlin, V. M., Leverenz, J. B., Bekris, L. M., Bird, T. D., Yuan, W., Elman, L. B., Clay, D., Wood, E. M., Chen-Plotkin, A. S., Martinez-Lage, M., Steinbart, E., McCluskey, L., Grossman, M., Neumann, M., Wu, I.-L., Yang, W.-S., Kalb, R., Galasko, D. R., Montine, T. J., Trojanowski, J. Q., Lee, V. M.-Y., Schellenberg, G. D., & Yu, C.-E.
Affiliations
  • University of Washington (US)
  • VA Puget Sound Health Care System (US)
  • University of Pennsylvania (US)
  • Institut für Neuropathologie (DE)
  • National Taiwan University (TW)
  • Children's Hospital of Philadelphia (US)
  • University of San Diego (US)
Corresponding author
Schellenberg, Gerard D
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2008-05
Volume
7
Issue
5
Pages
409-416
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2159556459
Cited by
723
References
39
Citations by year
2026: 13 · 2025: 28 · 2024: 28 · 2023: 20 · 2022: 36 · 2021: 30 · 2020: 30 · 2019: 27 · 2018: 43 · 2017: 22 · 2016: 30 · 2015: 38 · 2014: 44 · 2013: 45 · 2012: 47
FWCI
50.81
Type
journal article
Language
en
Open access
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging (P01AG014382, P30AG010124, P01AG017586, P50AG005136)
Topics
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
TARDBP, TDP-43, amyotrophic lateral sclerosis, familial ALS, frontotemporal lobar degeneration, FTLD-U, TDP-43 proteinopathy, glycine-rich domain, co-segregation, neurodegeneration
MeSH terms
Adolescent, Adult, Aged, Aged, 80 and over, Alanine, Amyotrophic Lateral Sclerosis, Brain, Child, Dementia, DNA Mutational Analysis, DNA-Binding Proteins, Family Health, Female, Glycine, Humans, Male, Middle Aged, Serine, Polymorphism, Single Nucleotide, Ubiquitin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review